Because patients need to take calcium supplementation for a long time after operation, which might last for more than 1 year or for lifetime [14] and the recurrence rate of hyperparathyroidism 6 months after operation might reach 30.8% [15], drug therapy is the first choice for SHPT patient and nonselective vitamin D receptor activators (VDRA), such as calcitriol, have been successfully used in the treatment of SHPT [16]. The gene discussed is VDR; the disease is hyperparathyroidism.